Amgen (AMGN): FY26 Q3 earnings call, Nov 3, 2026
On its Nov 3, 2026 earnings call (FY26 Q3), Amgen said 6 of the 14 words Kalshi listed; Parrot’s count agreed with all 14 settlements. Quotes below are at most 25 words each.
UpdatedMarkets
14 words · 6 settled yes · our count agreed on 14 of 14- Kalshi: company speakers + operator
Kalshi
| Word | Result | Our count | All speakers | Agrees | Probability | Market |
|---|---|---|---|---|---|---|
| Dazodalibep | Yes | 9 | 9 | ✓ | 70%transcripts from the transcript model | – |
| Eosinophilic | Yes | 6 | 6 | ✓ | 65%transcripts from the transcript model | – |
| ESMO | Yes | 5 | 7 | ✓ | 31%transcripts from the transcript model | – |
| Imfinzi / Durvalumab | Yes | 5 | 5 | ✓ | 20%transcripts from the transcript model | – |
| GLP-1 / GLP | Yes | 4 | 5 | ✓ | 78%transcripts from the transcript model | – |
| Medicare | Yes | 1 | 2 | ✓ | 39%transcripts from the transcript model | – |
| Oral 3+ times | No | 1 | 1 | ✓ | 55%transcripts from the transcript model | – |
| Artificial Intelligence 3+ times | No | 1 | 1 | ✓ | 28%transcripts from the transcript model | – |
| Tavneos | No | 0 | 0 | ✓ | 68%transcripts from the transcript model | – |
| Acquisition | No | 0 | 0 | ✓ | 53%transcripts from the transcript model | – |
| Prolia 2+ times | No | 0 | 0 | ✓ | 35%transcripts from the transcript model | – |
| Litigation | No | 0 | 0 | ✓ | 31%transcripts from the transcript model | – |
| Patent 2+ times | No | 0 | 0 | ✓ | 29%transcripts from the transcript model | – |
| Buyback / Buy Back | No | 0 | 0 | ✓ | 16%transcripts from the transcript model | – |
Market prices are mid quotes from Kalshi and Polymarket, shown for context, may be delayed by several minutes and are not a signal. Quotes as of Nov 3, 2026 23:56 UTC.
Transcript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
9 matches for “Dazodalibep”; 5 quoted, at least 25 words apart.
…cornerstone therapy, TEZSPIRE in eosinophilic esophagitis, an area with significant unmet need, and dazodalibep in Sjögren's disease, where no approved disease-modifying therapies currently exist.
…diseases: IMDELLTRA in small cell lung cancer, TEZSPIRE in eosinophilic esophagitis, and dazodalibep in Sjögren's disease. These results reflect our R&D strategy that focuses on…
…inflammation. For patients with Sjögren's disease, we are targeting CD40 ligand signaling with dazodalibep in two phase III trials, in systemic and in symptomatic disease.
…four and sustained through the end of study at week 48. Importantly, dazodalibep also met key secondary endpoints for patient-reported dryness, with statistically significant improvements…
…to invest in the innovation that will drive future growth, including MariTide, dazodalibep, and xaluritamig, as well as our marketed medicines, including IMDELLTRA, Repatha, and…
Where the listed words were said
…ago, we were delighted, but maybe not surprised by the impact of dazodalibep in Sjögren's disease. We were building on a very strong phase II…
…in the need for surgery. More recently, positive phase III results in eosinophilic esophagitis, or EoE, demonstrated meaningful improvements in key measures of disease activity…
…first-line maintenance study of IMDELLTRA with anti-PD-L1 therapy was also presented at ESMO, remarkably featuring a median overall survival of 37 months. These results are…
…phase III results from the DeLLphi-305 study evaluating IMDELLTRA in combination with IMFINZI in first-line maintenance treatment. I was at the European Society for Medical…
…start and stay on MariTide, and how others can switch from other GLP-1-based medicines and stay on MariTide. Our goal is to make long-term treatment…
…we're interested in seeing what other government access programs evolve to over time. I think it's good that we've got Medicare access in this category.
Agents: this page as TSV at /api/v1/appearances/amgen:2026-11-03:earnings_call · words: /api/v1/brief?appearance=amgen:2026-11-03:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP